Imcivree

Imcivree is a medicine used to treat obesity and help control hunger caused by certain genetic conditions that affect how the brain controls feelings of hunger. It is used in adults and children aged 6 years and older with Bardet Biedl syndrome (BBS), and in those who have pro-opiomelanocortin (POMC) deficiency or leptin receptor (LEPR) deficiency resulting from changes (mutations) in both copies of the genes responsible for making POMC or LEPR. Bardet Biedl syndrome, pro-opiomelanocortin deficiency and leptin receptor deficiency are rare, and Imcivree was designated an ‘orphan medicine’ (a medicine used in rare diseases). Further information on the orphan designations can be found on the European Medicines Agency’s website ( [pro-opiomelanocortin deficiency](/en/medicines/human/orphan-designations/eu-3-16-1703): 14 July 2016; [leptin receptor deficiency](/en/medicines/human/orphan-designations/eu-3-18-2101): 19 November 2018; [Bardet Biedl syndrome](/en/medicines/human/orphan-designations/eu-3-19-2192): 21 August 2019). Imcivree contains the active substance setmelanotide.